Anxiety Disorders with Comorbid Substance Use Disorders: Diagnostic and Treatment Considerations
Sudie E. Back, PhD; and Kathleen T. Brady, MD, PhD
Psychiatric Annals, Volume 38, Issue 11, NOVEMBER 2008

CME EDUCATIONAL OBJECTIVES

1. Understand the prevalence of co-occurring anxiety disorders and substance use disorders.
2. List the major diagnostic considerations in assessing co-occurring anxiety disorders among individuals with substance use disorders.
3. Demonstrate awareness of the pharmacologic and psychosocial treatments to date in this area.

ABOUT THE AUTHOR

Sudie E. Back, PhD; and Kathleen T. Brady, MD, PhD, are with the Clinical Neuroscience Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston. Address correspondence to: Sudie E. Back, PhD, 67 President Street, PO Box 250861, Charleston, SC 29425; fax: 843-792-0528; or e-mail backs@musc.edu.

Dr. Back and Dr. Brady have disclosed no relevant financial relationships.

INSTRUCTIONS

1. Review the stated learning objectives of the CME articles and determine if these objectives match your individual learning needs.
2. Read the articles carefully. Do not neglect the tables and other illustrative materials, as they have been selected to enhance your knowledge and understanding.
3. The following quiz questions have been designed to provide a useful link between the CME articles in the issue and your everyday practice. Read each question, choose the correct answer, and record your answer on the CME REGISTRATION FORM at the end of the quiz. Retain a copy of your answers so that they can be compared with the correct answers should you choose to request them.
4. Type your full name and address and your date of birth in the space provided on the CME REGISTRATION FORM.
5. Complete the evaluation portion of the CME REGISTRATION FORM. Forms and quizzes cannot be processed if the evaluation portion is incomplete. The evaluation portion of the CME REGISTRATION FORM will be separated from the quiz upon receipt at PSYCHIATRIC ANNALS. Your evaluation of this activity will in no way affect the scoring of your quiz.
6. Your answers will be graded, and you will be advised whether you have passed or failed. Unanswered questions will be considered incorrect. A score of at least 80% is required to pass. Your certificate will be mailed to you at the mailing address provided. Upon receiving your grade, you may request quiz answers. Contact our customer service department at (856) 994-9400.
7. Be sure to complete the CME REGISTRATION FORM on or before November 30, 2009. After that date, the quiz will close. Any CME REGISTRATION FORM received after the date listed will not be processed.
8. This activity is to be completed and submitted online only.

Indicate the total time spent on the activity (reading article and completing quiz). Forms and quizzes cannot be processed if this section is incomplete. All participants are required by the accreditation agency to attest to the time spent completing the activity.

CME ACCREDITATION

This CME activity is primarily targeted to patient-caring physicians specializing in psychiatry. There are no specific background requirements for participants taking this activity. Learning objectives are found at the beginning of each CME article.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vindico Medical Education and PSYCHIATRIC ANNALS. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Vindico Medical Education designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FULL DISCLOSURE POLICY

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears at the beginning of each CME-accredited article in this issue.

UNLABELED AND INVESTIGATIONAL USAGE

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
HOW TO OBTAIN CME CREDITS BY READING THIS ISSUE

This CME activity is primarily targeted to patient-caring physicians specializing in psychiatry. Physicians can receive AMA PRA Category 1 Credits™ by reading the CME articles in PSYCHIATRIC ANNALS and successfully completing the quiz at the end of the articles. Complete instructions are given subsequently. Educational objectives are found at the beginning of each CME article.

CME ACCREDITATION

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vindico Medical Education and PSYCHIATRIC ANNALS. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Vindico Medical Education designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FULL DISCLOSURE POLICY

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears at the beginning of each CME-accredited article in this issue.

UNLABELED AND INVESTIGATIONAL USAGE

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

EDUCATIONAL OBJECTIVES OVERVIEW

In this issue of Psychiatric Annals, the participant will become more familiar with the clinical implications of epidemiologic data for the diagnosis and treatment of psychiatric comorbidity; bipolar patients with comorbid substance use disorders; anxiety disorders with substance use disorders; and using meta-analysis to guide clinical recommendations for the treatment of co-occurring depression and substance dependence.

TABLE OF CONTENTS

709 Clinical Implications of Epidemiologic Data for Diagnosis and Treatment of Psychiatric Comorbidity
Sharon Samet, PhD; and Deborah Hasin, PhD

716 Diagnostic and Treatment Considerations: Bipolar Patients with Comorbid Substance Use Disorders
Ihsan Salloum, MD, MPH; Antoine Douaihy, MD; and Lauren Williams, MD

724 Anxiety Disorders with Comorbid Substance Use Disorders: Diagnostic and Treatment Considerations
Sudie E. Back, PhD; and Kathleen T. Brady, MD, PhD

730 Treatment of Co-occurring Depression and Substance Dependence
Edward V. Nunes, MD; and Frances R. Levin, MD

RESPONSIBILITY FOR STATEMENTS

All opinions expressed by authors and quoted sources are their own and do not necessarily reflect the opinions of the editors, publishers, or editorial boards of Psychiatric Annals or its employees. Vindico Medical Education or its employees, or the University of New Mexico. The acceptance of advertising in no way implies endorsement by the editors, publishers, or editorial boards of Psychiatric Annals.

The material presented at or in any Psychiatric Annals or Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education or Psychiatric Annals. Neither Psychiatric Annals, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. Articles are intended for informational purposes only and should not be used as the basis of patient treatment. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Copyright © 2008 by SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without prior written consent of the publisher.
Anxiety disorders, symptoms of anxiety, and substance use disorders (SUDs) commonly co-occur. The interactions between SUDs and anxiety are multifaceted and variable. Symptoms of anxiety often emerge during the course of chronic intoxication and withdrawal from a number of substances. Anxiety disorders are a risk factor for the development of SUDs and may modify the presentation and course of illness for SUDs. Similarly, SUDs may modify the presentation and course of anxiety disorders. In this article, co-occurring SUDs and anxiety disorders will be briefly reviewed, including prevalence, diagnostic issues, and treatment options.

**Epidemiology**

The most recent and largest (N > 43,000) comorbidity study to date, the National Epidemiological Survey on Alcohol and Related Conditions (NESARC), found that 17.7% of respondents with a current SUD also met criteria for an anxiety disorder. Treatment-seeking samples also demonstrate high rates of comorbid anxiety and SUDs. One study of 422 outpatients in the United States with opioid use disorders reported that 12% of men and 21% of women met criteria for an anxiety disorder. Treatment-seeking samples also demonstrate high rates of comorbid anxiety and SUDs. One study of 422 outpatients in the United States with opioid use disorders reported that 12% of men and 21% of women met criteria for a lifetime anxiety disorder. Merikangas and colleagues found that, in general, anxiety disorders precede the development of co-occurring alcohol (57% to 80%) and drug (67.6% to 100%) use disorders.

**Educational Objectives**

1. Understand the prevalence of co-occurring anxiety disorders and substance use disorders.
2. List the major diagnostic considerations in assessing co-occurring anxiety disorders among individuals with substance use disorders.
3. Demonstrate awareness of the pharmacologic and psychosocial treatments to date in this area.

Sudie E. Back, PhD; and Kathleen T. Brady, MD, PhD, are with the Clinical Neuroscience Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston.

Address correspondence to: Sudie E. Back, PhD, 67 President Street, PO Box 250861, Charleston, SC 29425; fax: 843-792-0528; or e-mail backs@musc.edu.

Dr. Back and Dr. Brady have disclosed no relevant financial relationships.
SCREENING AND DIFFERENTIAL DIAGNOSIS

One of the greatest difficulties in the area of co-occurring anxiety and SUDs is that of differential diagnosis. Substances of abuse impact the neurotransmitter systems involved in the pathophysiology of anxiety disorders and may unmask vulnerability or lead to organic changes that manifest as an anxiety disorder. The best way to differentiate substance-induced, transient symptoms of anxiety from anxiety disorders that warrant treatment is through observation of symptoms during a period of abstinence. Transient substance-induced symptoms improve with time. The duration of abstinence necessary for accurate diagnosis remains controversial and is likely to be based on both the diagnosis being assessed and the substance used. Long half-life drugs (eg, some benzodiazepines, methadone) may require several weeks of abstinence for withdrawal symptoms to subside. However, shorter-acting substances (eg, alcohol, cocaine, short half-life benzodiazepines) require shorter periods of abstinence to make valid diagnoses. A family history of anxiety disorder, the onset of anxiety symptoms before the onset of the SUD, and sustained anxiety symptoms during lengthy periods of abstinence all suggest an anxiety disorder that will need to be addressed with specific treatment.

ETIOLOGIC CONNECTIONS

A number of recent studies have focused on exploration of the etiologic relationships between anxiety and SUDs. Studies do not consistently support “self-medication” as an explanation for the relationship between anxiety and substance use. Although some substances can provide short-term relief of anxiety symptoms, in general there is anxiety induction with chronic substance use and withdrawal, which can initiate a feed-forward cycle of increasing anxiety symptoms and substance consumption.

In the basic science arena, the role of neuroadaptation and stress in relapse to substance use has been an area of intense investigation. Corticotrophiin releasing hormone (CRH), one of the key hormones involved in the stress response, has been implicated in the pathophysiology of anxiety, as well as in addictive disorders. Noradrenergic and other neurotransmitter systems, as well as endogenous opiates, may
also provide a neurobiologic link between anxiety and substance use disorders.

**GENERAL TREATMENT CONSIDERATIONS**

In general, treatment efforts addressing anxiety disorders and SUDs have developed in parallel. The integration of effective treatments from both fields will be critical to the optimal treatment of individuals with co-occurring disorders. It is important to maximize the use of nonpharmacologic treatments. Learning strategies to self-regulate anxiety symptoms can interrupt the “self-medication” cycle and help individuals to acquire alternative coping strategies. Among psychosocial treatments, cognitive behavioral therapies (CBT) are among the most effective for both anxiety disorders and SUDs. Promising pilot work investigating the integration of treatments to develop therapies specifically targeting co-occurring disorders will be discussed in the sections that follow.

Research investigating pharmacotherapeutic treatments for both SUDs and anxiety disorders is progressing rapidly. The pharmacotherapeutic treatment of specific anxiety disorders will be discussed, but there are some general issues that apply to the treatment of co-occurring disorders, which will be discussed in this section.

First, individuals in recovery from SUDs may have complex and conflicting feelings about the use of medications and may see the need for medications as a sign of defec- tiveness or failure. It is important to proactively discuss feelings and attitudes about medications and emphasize the need for medication adherence before prescribing. In cases where the relationship of psychiatric symptoms and substance use is unclear, the risk/benefit ratio of using medications must be carefully considered. When medications are used, treatment should generally follow routine clinical practice for treatment of the anxiety disorder with some exceptions. It is important to consider potential toxic interactions between the prescription medications and substances of abuse, in case relapse should occur. It is also important to use the agent with the least abuse potential. Despite their effectiveness in immediate relief of panic and other anxiety symptoms, benzodiazepines are generally not considered a “first-line” of treatment for SUD patients because of abuse potential. They may be considered as adjunctive medication during the early treatment phase when activation or latency of onset of the antidepressants is an issue. If a benzodiazepine is prescribed to a patient with a co-occurring SUD, close monitoring for relapse and limited amounts of medication should be given. Medication adherence contracts, similar to those used with chronic pain patients receiving prescription opioids, may also be useful in patients with a co-occurring SUD.

Finally, the use of agents specifically targeting SUDs in individuals with co-occurring anxiety disorders is under-explored. In one study of 254 outpatients with alcohol dependence and a variety of comorbid psychiatric disorders, Petrakis and colleagues investigated the efficacy of disulfiram and naltrexone, or their combination, in a 12-week randomized trial. Participants treated with either medication had significantly more consecutive weeks of abstinence and fewer drinking days per week. The effects of the medications by specific comorbid psychiatric disorder were not discussed, but active medication was associated with greater anxiety symptom improvement. No clear advantage of combining medications was observed.

In the sections that follow, the prevalence rates, differential diagnosis and treatment of specific anxiety disorders will be briefly reviewed.

**SPECIFIC DISORDERS**

**Generalized Anxiety Disorder**

SUDs are one of the most common co-morbid psychiatric disorders among individuals with generalized anxiety disorder (GAD). A recent epidemiologic study of 5,877 adults found that GAD was the anxiety disorder most often associated with using alcohol or drugs to self-medicate symptoms. Comorbid GAD is associated with an accelerated progression from first use to the onset of dependence, and the presence of comorbid SUDs has been shown to significantly decrease the likelihood of recovery from GAD.

As GAD symptoms can be mimicked by substance use or withdrawal, diagnostic complications can arise. Assessment of GAD should be delayed until intoxication or withdrawal has terminated. For short-acting drugs (eg, cocaine), it may be possible to assess GAD after one week of abstinence, but longer periods of time (eg, 4 to 8 weeks) may be required for longer-acting drugs (eg, methadone, valium). Patients should also be assessed for use of over-the-counter substances that can induce anxiety (eg, caffeine, diet pills). The Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), requires that a core number of anxiety symptoms be present for at least 6 months in order to meet diagnostic criteria for GAD. Substance use during those 6 months needs to be considered. Symptoms of GAD must have been present dur-
PTSD. Similarly, data from a more recent multisite longitudinal study of almost 1,000 individuals showed that a history of PTSD predisposes individuals to elevated rates of drug abuse and dependence. Among treatment-seeking substance abusers, the prevalence of lifetime PTSD has been reported as high as 50% or greater. In the majority of cases, the development of PTSD precedes the development of the SUD.

In comparison with other anxiety disorders, there is greater empirical research on the treatment of comorbid PTSD and SUDs. In a double-blind, placebo-controlled, 12-week trial, Brady and colleagues investigated the use of sertraline, which has been approved by the Food and Drug Administration (FDA) for the treatment of PTSD. The study included 94 individuals with PTSD and alcohol dependence. Individuals with less severe alcohol dependence and early onset PTSD demonstrated greater improvement in alcohol use severity when treated with sertraline as compared to placebo. Among 254 outpatients with alcohol dependence and comorbid psychiatric disorders (42.9% met DSM-IV criteria for comorbid PTSD), Petrakis and colleagues found that patients treated with naltrexone or disulfiram, as compared with placebo, had more consecutive weeks of abstinence and fewer drinking days per week. In comparison with naltrexone-treated participants, disulfiram-treated participants reported less craving from pre- to post-treatment. No clear advantage of combining disulfiram and naltrexone was observed.

A number of investigations of integrative psychotherapies have demonstrated that addressing trauma/PTSD among SUD patients is beneficial and typically leads to significant reductions in both PTSD and SUD symptoms. The most widely studied integrated therapy to date is Seeking Safety (SS), a 25-session, manualized treatment that provides psychoeducation and teaches coping skills. In a controlled study, 107 women were randomized to SS, relapse prevention (RP), or treatment-as-usual (TAU). Patients who received TAU failed to show improvement (and in the case of PTSD symptoms, worsened over time), while patients who received either SS or RP demonstrated significant improvement in substance use, PTSD, and global psychiatric symptoms. No significant difference between SS and RP treatment groups were observed.

To date, two small studies have systematically examined treatments that integrate gold-standard exposure-based techniques for PTSD with empirically validated treatments for SUDs. Triffleman and colleagues developed a 20-week, manualized treatment that utilizes RP, coping skills, psychoeducation, and in vivo exposure. In a small (N = 19) pilot trial it was shown to be as effective as, but not superior to, Twelve-Step Facilitation Therapy with regard to PTSD symptoms and drug use. In another uncontrolled trial (N = 39), Brady and colleagues developed a 16-session, manualized treatment consisting of combined imaginal and in vivo exposure therapy for PTSD and cognitive-behavioral RP techniques for cocaine dependence. The intervention was associated with significant reductions in all three clusters of PTSD symptoms and cocaine use. Several other studies have preliminarily explored the use of psychosocial treatments among SUD/
PTSD patients with favorable results. Although more randomized, controlled trials in this area are needed, the studies to date demonstrate that for the majority of SUD/PTSD patients, addressing PTSD confers substantial therapeutic benefits.

Social Phobia

Data from the NCS found that 16.4% of socially phobic individuals endorsed self-medicating with alcohol and drugs. Individuals with social phobia (SP) are two to three times more likely than individuals without SP to develop an alcohol use disorder. As the average onset of social phobia is before adolescence, symptoms of social anxiety typically precede the initiation of alcohol or drug use.

In a placebo-controlled trial, Randall and colleagues examined the effectiveness of paroxetine, an SSRI, in 15 outpatients with alcohol dependence and SP. The paroxetine-treated group had significantly lower SP symptoms at the end of the 8-week trial, as compared with the placebo group; however, no significant group differences in measures of alcohol use severity were revealed. Gabapentin is an anticonvulsant agent with demonstrated efficacy in the treatment of SP. This is of particular interest because gabapentin has also demonstrated efficacy in the treatment of alcohol withdrawal and unlike benzodiazepines, gabapentin has no abuse potential. One case report of a polysubstance-dependent individual with comorbid SP who was treated with gabapentin documented significant improvement in craving and substance use, but there are currently no controlled trials examining the efficacy of gabapentin in co-occurring SP and SUDs.

Several controlled trials have examined the efficacy of psychosocial treatments for SP/SUD patients. In 93 outpatients with comorbid SP and alcohol dependence, Randall and colleagues compared a 12-week, manual-based CBT for alcohol dependence with an integrated manual-based CBT for both disorders. Contrary to expectations, patients who received the alcohol dependence-only treatment evidenced better outcomes than patients who received the integrated treatment. Although the reasons for this unexpected finding are unclear, the authors hypothesized that exposure to feared social situations during early recovery may have led to increases in alcohol use to cope. Schade and colleagues randomly assigned 96 individuals with alcohol dependence and comorbid SP and/or agoraphobia to receive relapse prevention (RP), or RP plus CBT for the anxiety disorder. The majority (89/96) of the sample had SP. Both groups were offered concomitant SSRI pharmacotherapy (fluvoxamine), but almost half (53%) refused it. Individuals who received the combined psychosocial treatment (alcohol + anxiety) had significantly greater improvement in anxiety symptoms than those who received treatment addressing alcohol dependence only. No significant differences between groups in alcohol use severity were observed and the use of fluvoxamine was not associated with improved anxiety or alcohol use severity outcomes.

Obsessive-compulsive Disorder

In comparison with other anxiety disorders, the association between obsessive compulsive disorder (OCD) and SUDs is less robust. For example, in a clinical sample of 254 individuals, approximately 4% of OCD patients met criteria for a lifetime SUD. The lower rates of OCD among SUD patients may be due, in part, to the generally low levels of impulsive or spontaneous behaviors and high levels of harm avoidance exhibited among individuals with OCD. When OCD patients do use substances, they typically choose sedating agents (eg, alcohol, marijuana).

Some substances of abuse (eg, alcohol, stimulants) and medications (eg, benzodiazepines) can produce obsessive-compulsive behaviors. This potential confound should be ruled out when diagnosing OCD among SUD patients. In general, the differential diagnosis of OCD in individuals with SUDs is not as difficult as that of some of the other anxiety disorders because there is less symptom overlap. For SUD patients, the content of obsessions and compulsions is restricted to alcohol or drug use. Obsessions and compulsions focused on procuring and using drugs alone, or that occur only during intoxication, do not meet diagnostic criteria for OCD.

Little research on the treatment of co-occurring OCD and SUDs has been conducted to date. There are no randomized controlled trials examining the use of a pharmacologic treatment for this patient population. SSRIs have been shown to be effective in treating OCD among non-substance dependent patients and would likely be helpful among SUD patients, but this has not been systematically tested. One controlled clinical trial has demonstrated promising results for an integrated OCD/SUD psychotherapy.

CONCLUSIONS

Interest in the co-occurrence of anxiety disorders and SUDs has grown tremendously in recent years, as the evidence of the prevalence and impact of comorbidity has become increasingly clear. There have been a number of recent advances in the treatment of both anxiety disorders and SUDs, and treatment addressing both disorders can improve long-term therapeutic outcomes. Specific considerations in choosing a pharmacologic agent for use in patients with SUDs include safety, toxicity, and abuse liability. In conclusion, although the co-occurrence of SUDs and anxiety disorders is an important area in which recent developments provide cause for considerable optimism, much work remains to be done.

REFERENCES


2. Kidorf M, Disney ER, King VL, Neufeld K, Beilenson PL, Broomer RK. Prevalence...


